An FDA advisory committee has recommended that six peptide substances be considered for a federal list that can allow their use in certain patient-specific compounded medicines. The recommendation does not put the ingredients on the list, does not authorize retail sales without a prescription and does not mean the substances are FDA-approved drugs for obesity, wound healing, insomnia, migraine or other proposed uses.
The Pharmacy Compounding Advisory Committee reached its recommendations after a two-day meeting July 23 and 24 on seven peptide-related bulk drug substances. The panel backed BPC-157, KPV, TB-500, MOTS-C, epitalon and semax, while declining to recommend emideltide, also known as DSIP, according to ABC News and the regulatory publication Regulatory Focus. The practical stakes now rest with the Food and Drug Administration, which must decide whether to propose any changes through formal rulemaking.
What the committee considered
The FDA meeting agenda grouped the substances with specific nominated uses. BPC-157 was proposed for ulcerative colitis; KPV for wound healing and inflammatory conditions; TB-500 for wound healing; and MOTS-C for obesity and osteoporosis. The second day covered emideltide for insomnia, narcolepsy and opioid withdrawal; semax for cerebral ischemia, migraine and trigeminal neuralgia; and epitalon for insomnia.
The committee’s reported outcome was not a clinical finding that any peptide works for those conditions. It was advice on whether the substances meet criteria for potential placement on the Section 503A Bulks List, an FDA list governing which bulk drug ingredients may be used by eligible state-licensed physicians and pharmacies in patient-specific compounding when other legal requirements are satisfied.
Regulatory Focus reported a 6-7 vote, with one abstention, against recommending emideltide. It reported votes of 7-5 with one abstention for epitalon and 8-5 for semax. Publicly available material does not provide official vote totals for BPC-157, KPV, TB-500 or MOTS-C, though both news reports described all four as recommended. The FDA agenda verifies what was scheduled for discussion but does not supply a final vote transcript.
A recommendation is not a drug approval
The distinction is consequential for patients and prescribers. Compounded drugs are made for identified patients rather than reviewed and approved as finished products through the FDA’s standard premarket process. The agency’s Section 503A compounding guidance says that a bulk substance on the list may be used only if applicable statutory conditions and compounding-quality requirements are met. A listing would not itself establish a product’s safety, effectiveness or quality for a nominated use.
The advisory committee is not the final decision-maker. FDA advisory panels provide independent expert advice, but the agency is not legally bound to follow it. FDA says additions to the 503A Bulks List are made through notice-and-comment rulemaking, a process that would require a proposed action, an opportunity for public comment and a final agency decision. No final FDA addition of these six substances is documented.
That leaves several possible outcomes: FDA could pursue all, some or none of the recommendations, and any proposal could draw comments about the clinical evidence, manufacturing controls and the role of compounding when approved therapies exist. A committee vote therefore does not mean a newly prescribed compounded peptide will become broadly available immediately.
Thin clinical evidence and quality questions remained
FDA staff scientists opposed adding all seven substances, citing limited robust clinical evidence, inconsistency between batches and the possibility of harmful immune reactions, according to ABC News. The concerns are especially relevant for peptides, whose manufacturing can create impurities or related compounds that may complicate assessment of a finished preparation. Those concerns do not prove that every compounded product will cause harm; they describe uncertainties and potential risks the agency considers when evaluating bulk substances.
The agency had previously identified several of the peptides at issue, including BPC-157, KPV, MOTS-C and epitalon, in a framework for bulk substances that may pose significant safety risks. On its safety-risk page, FDA describes gaps in safety information and concerns that can include immunogenicity and peptide-related impurities. Such agency assessments should not be read as proof that a reported adverse event was caused by a particular peptide, but they underscore why evidence and product-quality questions remain central.
The record discussed for emideltide illustrates the limits of the evidence considered. ABC News reported that support included one narcolepsy case report and two small, uncontrolled studies related to opioid withdrawal. The studies used intravenous administration, while the compounding nomination proposed subcutaneous injection. Differences in route of administration can affect how a drug is absorbed and how its effects and risks are evaluated, so evidence from one route cannot automatically establish outcomes for another.
Regulatory Focus reported that FDA briefing materials found insufficient evidence of safety and effectiveness for emideltide’s proposed uses and noted that approved therapies are available for them. The reported rejection of emideltide does not, however, establish a uniform evidence threshold across the other six nominations; the available public accounts do not provide complete briefing materials or an official explanation for every individual vote.
Why the decision could affect a growing market
Some committee members argued that allowing physician-directed compounding could reduce risks for people who otherwise buy products sold online as research chemicals, ABC News reported. That is an argument about a potential regulatory pathway, not evidence that broader availability would necessarily improve safety. FDA staff concerns described in the news reports focused on the opposite possibility: that limited clinical data and uncertain product quality could expose patients to poorly characterized treatments.
For now, people taking or considering any compounded medication should not make treatment changes based on the committee vote alone and should discuss their circumstances with a licensed clinician. The next material sign of change would be an FDA rulemaking proposal, where the agency would have to explain how it weighed the panel’s advice against the unresolved evidence and safety questions.
